Solteq reports Q4’24 results on Thursday, February 13th.
Redeye gives a short comment on the news that Saniona’s partner Medix will file a final version of T...
Weak order trend broken, orders +29% y-o-y, above our flat estimate '25e-'26e orders +7%, sales +4%,...
We expect two more quarters before a return to growth '25e-'26e EBIT down 19-7%; 26% CAGR '24-'27e 2...
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...
Plejds nettoomsättning för det fjärde kvartalet 2024 uppgick till 204,0 MSEK (161,9), en ökning med ...
Redeye state Gapwaves delivered a strong report with Net sales and EBITDA excl.
Redeye argues that AVTECH has secured double-digit growth following the LATAM Airlines agreement sig...
Redeye retains its positive stance towards Hexatronic following a Q4 report that matches our expecta...
Order intake +37% y-o-y on return of one key customer '25-'26e EBIT up 13-6% on higher gross margin ...
Conditions remain stable but unfavourable We cut '25e-'26e sales by 9-8% due to the divestment '25e-...
Ökad försäljning och lönsamhet EQL Pharma ökade nettoomsättningen med 31,3 procent, främst drivet av...
Consti's net sales in Q4 amounted to EUR 92.3m, slightly above our estimates (Evli est.
Orders recover sharply, +30% y-o-y, and sales beat our est.
Solid Q4 finish but cautious Q1/H1'25 guidance Pick-up in OEM/VIP but destocking holds back AM Negat...
